Exicure Announces Presentation at 2021 BIO CEO & Investor Digital Conference
Exicure, Inc. (Nasdaq: XCUR) announced that CEO David Giljohann will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available for on-demand viewing for registered attendees beginning February 15, 2021. Attendees can schedule 1x1 meetings with Exicure during the conference. With a focus on gene regulatory and immunotherapeutic drugs, Exicure is developing therapeutics targeting neurological and inflammatory diseases utilizing its proprietary Spherical Nucleic Acid (SNA) technology.
- CEO David Giljohann's participation in a notable industry conference may enhance Exicure's visibility among investors.
- The company continues to advance its SNA technology, which has distinct therapeutic potential.
- None.
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced that David Giljohann, CEO, will present at the 2021 BIO CEO & Investor Digital Conference, February 16-18, 2021.
The presentation will be available to registered conference attendees for on-demand viewing beginning February 15, 2021 at 9:00AM ET via the virtual conference link.
Registered conference attendees may schedule a 1x1 meeting with Exicure via the conference scheduling link.
Replays of the presentation will be available on Exicure’s website for 30 days following the presentation.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN an SNA–based therapeutic candidate, for the treatment of Friedreich’s ataxia (FA). Exicure's drug candidate AST-008 is currently in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is in Chicago, IL and has an office in Cambridge, MA.
For more information, visit Exicure’s website at www.exicuretx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005071/en/
FAQ
What is the purpose of Exicure's presentation at the BIO CEO & Investor Digital Conference?
When will Exicure's presentation be available for viewing?
What key technologies does Exicure focus on?
What therapeutic areas is Exicure targeting?
Where can I find more information about Exicure?
